Navigation Links
Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List
Date:12/5/2008

MANCHESTER, N.H., Dec. 5 /PRNewswire/ -- Anthem Blue Cross and Blue Shield in New Hampshire has once again ranked among the very best health insurers, according to the current issue of U.S. News & World Report/NCQA America's Best Health Plans 2008. This recognition as one of the nation's best health plans is the result of outstanding overall performance in clinical care measures, member satisfaction and NCQA accreditation.

Anthem Blue Cross and Blue Shield in New Hampshire was rated 20th out of the 239 ranked health plans in the country.

"This recognition is due to the hard work of our associates and a testament to all they do on behalf of our members," said Douglas J. Wenners, president and general manager, Anthem Blue Cross and Blue Shield in New Hampshire. "We are excited and proud to be counted among the nation's top plans yet again."

Anthem Blue Cross and Blue Shield in New Hampshire currently holds Excellent Accreditation for its HMO/POS plan and has earned Quality Plus Distinction in Care Management and Health Improvement. The plan scored in the 90th percentile (i.e., the top 10 percentile of health plans in the nation) in several key Healthcare Effectiveness Data and Information Set *(HEDIS(R)) Effectiveness of Care measures, including preventive screenings for breast, cervical and colorectal cancer; diabetes measures related to HbA1c (blood sugar control) testing, HbA1c control, eye care, control of cholesterol, control of blood pressure (<140/90), cholesterol management, prenatal care, and access to preventive services for adults 20-64, access to PCP for children ages 2-6 and adolescents ages 12-19.

"As the state's largest health insurer, a major part of our mission is to improve the health status of New Hampshire residents," Wenners added. "Our work on these critical areas, as well as our continued emphasis on key population health measures, is vital to that missi
'/>"/>

SOURCE Anthem Blue Cross and Blue Shield in New Hampshire
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations
2. Anthem Blue Cross Gives the Gift of Health to California
3. Anthem Blue Cross and Blue Shield in Maine Associates Pledge More Than $277,500 to Community Organizations
4. Anthem Blue Cross and Blue Shield and Anthem Life in Connecticut Partner with the Chamber Insurance Trust to Offer Life and Disability Products to Chamber of Commerce Members
5. Anthem Blue Cross and Blue Shield in Connecticut Ranks in Top 10 of Insurers Nationwide on U.S. News & World Report/National Committee for Quality Assurance Americas Best Health Plans List
6. Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program
7. Anthem Blue Cross and Blue Shield Foundation Awards $100,000 Grant to Shoreline Greenway Trail
8. Anthem Blue Cross and Blue Shield in Maine Among Top Insurers on U.S. News & World Report/National Committee for Quality Assurance Americas Best Health Plans List
9. American Lung Association of Nevada Receives $150,000 Grant from Anthem Blue Cross and Blue Shield Foundation to Help Nevadas Youth Stay Smoke-Free
10. Anthem Blue Cross and Blue Shield in Maine Ranks in Top 6% of all insurers on U.S. News & World Report/National Committee for Quality Assurance Best Health Plans List
11. Anthem Blue Cross and Blue Shield Staff to Participate in WTMJ-TV Health Insurance Phone Bank
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10